RadioBDC Logo
Catch The Sun | Doves Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

After Lipitor, Pfizer must chart its course by a new set of stars

Pfizer Inc., which lost patent protection on its best-selling Lipitor, will refocus on development of biologic drugs and specialty medicines, and promoting existing products overseas. Pfizer Inc., which lost patent protection on its best-selling Lipitor, will refocus on development of biologic drugs and specialty medicines, and promoting existing products overseas. (Timothy A. Clary/AFP/Getty Images/File)
By Drew Armstrong
Bloomberg News / December 1, 2011
Text size +
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.

Pfizer’s long dependence on the cholesterol pill Lipitor to produce almost one-fifth of the company’s revenue began to erode Wednesday when the drug’s patent protection ended in the United States. The next step will be rebuilding the world’s biggest drugmaker into a smaller, faster-moving company that focuses on development of biologic drugs and specialty medicines while expanding sales of existing products, such as Lipitor and the erection drug Viagra, in emerging counties such as China, executives said in interviews.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.
  • E-mail
  • E-mail this article

    Invalid E-mail address
    Invalid E-mail address

    Sending your article

    Your article has been sent.